2022-10-14T07:42:51-05:00 2021-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2021-01-12 861884515 DAVOS ALZHEIMER'S COLLABORATIVE INC DAVO 7035999617 1101 K STREET NW 400 WASHINGTON DC 20005 ANDREW HOLZAPFEL COO 7035999617 2022-10-14 1 ANDREW HOLZAPFEL 999009999 RICHARD J LOCASTRO CPA P00288314 3019519090 0 AAL1 IAL1 2021 2022-09-23 18:48:47Z X GEORGE VRADENBURG 1101 K STREET NW 400 WASHINGTON DC 20005 14514120 0 X WWW.DAVOSALZHEIMERSCOLLABORATIVE.ORG X 2020 DC SEE PART III LINE 1. 3 3 0 3 0 0 14514120 0 0 0 14514120 343000 0 0 0 302565 2424999 2767999 11746121 12443051 696930 11746121 X DAVOS ALZHEIMER'S COLLABORATIVE, INC. (DAC) IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW-AND MIDDLE-INCOME COUNTRIES LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI THE VACCINE ALLIANCE, COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI), AND THE GLOBAL FUND. 0 0 1408832 335500 GLOBAL COHORTS - DAC IS BUILDING GLOBAL COHORTS TO ADVANCE UNDERSTANDING OF ALZHEIMER'S AMONG DIVERSE POPULATIONS. THIS DATA WILL PROVIDE THE FOUNDATION FOR IDENTIFYING NEW BIOMARKERS AND DEVELOPING TARGETED TREATMENTS THAT WORK FOR PEOPLE WORLDWIDE. IN 2021, DAC COMPLETED A CROSS-REGION HETEROGENEITY EXPLORATION PILOT (PRS) TO ENGAGE COHORTS. THIS INCLUDED THE MIDDLE EAST, SOUTH EAST ASIA, AFRICA AND SOUTH AMERICA AND CONNECT WITH MORE ADVANCED COHORTS IN THE WESTERN WORLD TO TEST OUR ABILITIES TO COMBINE AND FEDERATE DATA AND PROVIDE A ROADMAP FOR FURTHER INTEGRATION OF RACIALLY DISTINCT AND DIVERSE COHORTS. DAC RECRUITED 14 COHORTS AROUND THE GLOBE. OUTREACH TO COHORTS WERE TARGETED THAT HAVE THE STRONGEST ALIGNMENT WITH THE SCIENTIFIC PLAN AND ACCESS TO THE TARGETED MEASUREMENTS. 405788 6000 HEALTHCARE SYSTEM PREPAREDNESS - DAC IS INVESTING TO TRANSFORM THE WAY HEALTHCARE SYSTEMS WORLDWIDE DETECT, DIAGNOSE AND TREAT ALZHEIMER'S. THE GOAL IS TO TAKE ADVANTAGE OF FUTURE INNOVATIONS TO IMPROVE THE QUALITY OF LIFE FOR PEOPLE EVERYWHERE. IN 2021, DAC INITIATED 7 FLAGSHIP PROJECTS IN 6 COUNTRIES. THE INITIAL CENTRALLY-DRIVEN PROJECT FOCUSED ON EARLY DETECTION. DAC ISSUED RFP FOR LOCALLY-DRIVEN PROJECT PROPOSALS THAT FOCUSED ON EARLY DETECTION. OVER 70 RESPONSES FROM 21 COUNTRIES WERE RECEIVED IN 2021. 271700 1500 GLOBAL CLINICAL TRIALS - DAC IS BUILDING A GLOBAL NETWORK OF CLINICAL TRIAL SITES AND A SUPPORTING TECHNOLOGY PLATFORM TO REDUCE THE COST AND TIME OF BRINGING NEW TREATMENTS TO MARKET. DAC DEVELOPED A NETWORK OF MORE THAN 15 EUROPEAN SITES ORGANIZED FOR ACCELERATING STUDIES AND IMPLEMENTING NOVEL TRIAL DESIGNS. DAC VALUATED SITES GLOBALLY AND IDENTIFIED OPPORTUNITIES IN AFRICA, SOUTH KOREA, SINGAPORE, AUSTRALIA, JAPAN AND CHINA. 2086320 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 17 0 1 0 0 1 SZ 0 0 0 0 0 0 0 0 0 0 X 3 3 0 1 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 0 0 0 X X X JENNIFER K SMITH 3012520563 2030 FLOWERING TREE TERRACE SILVER SPRING MD 20902 X GEORGE VRADENBURG CHAIR & PRESIDENT 20.00 X X 0 0 0 ANDREW HOLZAPFEL COO 30.00 X X 0 0 0 FREDA LEWIS HALL TREASURER 1.00 X X 0 0 0 0 0 0 0 0 0 0 HIGH LANTERN GROUP 685 THIRD AVE 22ND FLOOR NEW YORK NY 10017 ADMIN, MARKETING, PR, AND IT 608934 GLOBAL GENOMIC MEDICINE COLLABORATIVE 1821 HILLANDAKE ROAD SUITE 1B-254 DURHAM NC 27705 COHORT DATA ANALYSIS 555141 WEBER SHANDWICK 909 THIRD AVE NEW YORK NY 10022 MEDIA RELATIONS 218787 GLOBAL ALZHEIMER'S PLATFORM FOUNDATION 1101 K STREET NW SUITE 400 WASHINGTON DC 20005 CLINICAL TRIAL INNOVATION 199518 AD ASTRA ASSOCIATES LLC 55 EAST 87TH STREET 4JK NEW YORK NY 10128 DEVELOP A RESOURCE MOBILIZATION PLAN 172982 8 14514120 14514120 14514120 0 0 0 X 343000 343000 608934 243573 243574 121787 196900 129902 56842 10156 36314 14526 14525 7263 1336465 1246257 60139 30069 232788 101515 131273 2918 1168 1167 583 135 54 54 27 4920 2638 1521 761 3125 1250 1250 625 PROGRAM COSTS 2395 2395 SUBSCRIPTION FEES 105 42 42 21 2767999 2086320 379114 302565 12435461 7590 0 12443051 696930 0 696930 X 11146121 600000 0 11746121 0 12443051 11746121 0 X 0 1 X 1 0 X 14514120 14514120 14514120 14514120 10738872 3775248 14514120 X FORM 990, SCHEDULE A, PART II, LINE 1 THIS IS THE FIRST YEAR OF THE ORGANIZATION AND EXEMPTION WAS GRANTED ON 1/12/2021 MAKING 2021 A SHORT-YEAR. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 14568744 54624 54624 14514120 0 14514120 2768019 20 20 2767999 0 2767999 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2021, DAC HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE COMBINED FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: RELATED ORG. REVENUE REPORTED ON THE FINANCIAL 54,624. STATEMENTS, BUT EXCLUDED FROM PART VIII OF THE FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: RELATED ORG. EXPENSES REPORTED ON THE FINANCIAL 20. STATEMENTS, BUT EXCLUDED FROM PART IX OF THE FORM 990. 1 BOSTON UNIVERSITY SCHOOL OF MEDICINE 72 EAST COUNCIL STREET L103 BOSTON MA 02118 042103547 501(C)(3) 313000 0 SUPPORT BOSTON UNIVERSITY AND THE PURPOSE OF THE DAVOS ALHEIMER'S COLLABORATIVE FUND. RESTRICTED FUND FOR SUPPORT OF THE WORK OF DR. RHODA AU ALZEHEIMER'S DISEASE RESEARCH. USAGAINSTALZHEIMERS PO BOX 34565 WASHINGTON DC 20043 450672514 501(C)(3) 25000 0 LAUSANNE VIII WORKSHOP SPONSORSHIP 2 0 PART I, LINE 2: DAVOS ALZHEIMERS COLLABORATIVE, INC. (DAC) HAD MONTHLY CALLS WITH THE BOSTON UNIVERSITY SCHOOL OF MEDICINE LEADERSHIP TO ENSURE PROGRESS. ALL OTHER GRANTEES ARE REQUIRED TO PROVIDE A MIDTERM REPORT, A FINAL REPORT AND PARTICIPATE IN REGULAR MEETINGS TO PROVIDE UPDATES. THESE MEETINGS RANGE FROM MONTHLY CALLS TO MULTIDAY IN-PERSON WORKING SESSIONS. ADDITIONALLY, DAC LEADERSHIP, INCLUDING BOARD MEMBERS, HAVE TAKEN SITE VISITS TO SELECTED SITES TO ENSURE PROGRESS. FORM 990, PART VI, SECTION A, LINE 3 THE DAVOS ALZHEIMERS COLLABORATIVE, INC. (DAC) RETAINED AN INDEPENDENT CONTRACTOR, HIGH LANTERN GROUP, LLC (HLG), TO PROVIDE A SUITE OF MANAGEMENT SERVICES AND ADMINISTRATIVE SUPPORT, AS WELL AS THOSE DUTIES CUSTOMARILY PERFORMED BY AN ORG. CHAIR/PRESIDENT AND COO. DAC COMPENSATED HLG $608,934 FOR THOSE SERVICES. THE DUTIES OF THE CHAIR/PRESIDENT AND COO WERE PROVIDED TO DAC BY GEORGE VRADENBURG AND ANDREW HOLZAPFEL, RESPECTIVELY. OF THE $608,934 COMPENSATION PAID TO HLG BY DAC, $29,331 IS RELATED TO THE SERVICES PROVIDED BY ANDREW HOLZAPFEL. GEORGE VRADENBURG DOES NOT RECEIVE ANY SALARY OR PAYMENT. FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION HAS NO COMMITTEE WITH THE AUTHORITY TO ACT ON BEHALF OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTANTS. THE 990 WAS THEN REVIEWED WITH DAC'S COO AND CHAIR/PRESIDENT WITH THE AUDITORS. IT WAS THEN SHARED WITH THE BOARD AND FINALIZED UPON APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS, DIRECTORS OR TRUSTEES AND KEY EMPLOYEES(CONTRACTORS) ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY AT THE FIRST BOARD MEETING OF THE YEAR AND UPON CONTRACTING OR DATE OF HIGHER. IF A CONFLICT OF INTEREST IS FOUND, THE MATTER IS PRESENTED TO THE BOARD. THE APPLICABLE INTERESTED PERSON MAKES A PRESENTATION AT THE BOARD MEETING, BUT AFTER THE PRESENTATION, HE OR SHE REFRAINS FROM VOTING OR OTHERWISE ATTEMPTING TO EXERT ANY INFLUENCE ON WHETHER THE CORPORATION SHOULD PARTICIPATE OR NOT PARTICIPATE IN SUCH TRANSACTION AND LEAVES THE MEETING DURING THE DISCUSSION OF, AND VOTE ON, THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. AFTER EXERCISING DUE DILIGENCE, THE BOARD DETERMINES WHETHER THE CORPORATION CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, THE BOARD DETERMINES BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE CORPORATION'S BEST INTEREST, WHETHER IT IS FAIR, REASONABLE, AND THE RESULT OF ARM'S-LENGTH BARGAINING, AND WHETHER IT REFLECTS REASONABLE INVESTMENT CRITERIA OR PAYMENTS FOR GOODS AND SERVICES, FURTHERS THE CORPORATION'S PURPOSES AND DOES NOT RESULT IN PRIVATE INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR AN EXCESS BENEFIT TRANSACTION. IN CONFORMITY WITH THE ABOVE DETERMINATION, THE BOARD OR COMMITTEE MAKES ITS DECISION IN WRITING AND ON THE RECORD AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROF. FEES: PROGRAM SERVICE EXPENSES 60,139. MANAGEMENT AND GENERAL EXPENSES 60,139. FUNDRAISING EXPENSES 30,069. TOTAL EXPENSES 150,347. OTHER PROGRAM SERVICES: PROGRAM SERVICE EXPENSES 39,690. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 39,690. COHORT DATA ANALYSIS: PROGRAM SERVICE EXPENSES 555,141. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 555,141. MEDIA RELATIONS: PROGRAM SERVICE EXPENSES 218,787. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 218,787. CLINICAL TRIAL INNOVATION: PROGRAM SERVICE EXPENSES 199,518. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 199,518. RESOURCE PLAN DEVELOPMENT: PROGRAM SERVICE EXPENSES 172,982. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 172,982. DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) COURS DE RIVE 13 C/O PESTALOZZI AV GENEVE SW 1204 PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH. SW N/A N/A DAC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0